ImmuCell Net Worth
ImmuCell Net Worth Breakdown | ICCC |
ImmuCell Net Worth Analysis
ImmuCell's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ImmuCell's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ImmuCell's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ImmuCell's net worth analysis. One common approach is to calculate ImmuCell's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ImmuCell's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ImmuCell's net worth. This approach calculates the present value of ImmuCell's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ImmuCell's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ImmuCell's net worth. This involves comparing ImmuCell's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ImmuCell's net worth relative to its peers.
Enterprise Value |
|
To determine if ImmuCell is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ImmuCell's net worth research are outlined below:
| ImmuCell appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43. | |
| ImmuCell has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production ... |
ImmuCell uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ImmuCell. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ImmuCell's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
ImmuCell Target Price Consensus
ImmuCell target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. ImmuCell's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most ImmuCell analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand ImmuCell stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of ImmuCell, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmuCell Target Price Projection
ImmuCell's current and average target prices are 5.50 and 14.00, respectively. The current price of ImmuCell is the price at which ImmuCell is currently trading. On the other hand, ImmuCell's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On ImmuCell Target Price
Know ImmuCell's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ImmuCell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmuCell backward and forwards among themselves. ImmuCell's institutional investor refers to the entity that pools money to purchase ImmuCell's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prosperity Planning, Inc. | 2024-09-30 | 16 K | Ubs Group Ag | 2024-09-30 | 15.9 K | Blackrock Inc | 2024-09-30 | 14.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 12.2 K | Essex Financial Services, Inc. | 2024-09-30 | 11 K | Hm Payson & Co | 2024-09-30 | 4 K | Bank Of America Corp | 2024-09-30 | 2.1 K | Tower Research Capital Llc | 2024-09-30 | 1.1 K | Jones Financial Companies Lllp | 2024-09-30 | 19.0 | Cresset Asset Management, Llc | 2024-09-30 | 264 K | Vanguard Group Inc | 2024-09-30 | 225.6 K |
Follow ImmuCell's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.08 M.Market Cap |
|
Project ImmuCell's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.12) | (0.11) | |
| Return On Capital Employed | (0.13) | (0.12) | |
| Return On Assets | (0.12) | (0.11) | |
| Return On Equity | (0.21) | (0.20) |
When accessing ImmuCell's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ImmuCell's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ImmuCell's profitability and make more informed investment decisions.
Please note, the presentation of ImmuCell's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ImmuCell's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ImmuCell's management manipulating its earnings.
Evaluate ImmuCell's management efficiency
ImmuCell has return on total asset (ROA) of (0.0487) % which means that it has lost $0.0487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.161) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.11. The current year's Return On Capital Employed is expected to grow to -0.12. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 36.5 B, whereas Non Currrent Assets Other are forecasted to decline to about 49.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.92 | 2.10 | |
| Tangible Book Value Per Share | 2.91 | 2.06 | |
| Enterprise Value Over EBITDA | (19.73) | (20.72) | |
| Price Book Value Ratio | 1.80 | 1.79 | |
| Enterprise Value Multiple | (19.73) | (20.72) | |
| Price Fair Value | 1.80 | 1.79 | |
| Enterprise Value | 49.4 M | 51.9 M |
ImmuCell showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 2.447 | Revenue | Quarterly Revenue Growth 0.549 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmuCell insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmuCell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmuCell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ImmuCell Corporate Filings
8K | 16th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of September 2024 Other Reports | ViewVerify | |
F3 | 27th of August 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
ImmuCell Earnings per Share Projection vs Actual
When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 0.549 | Return On Assets |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.